ICYMI: THE COST OF BIG PHARMA’S EGREGIOUS PATENT ABUSE ON BRAND NAME INHALERS

06-2-2023 Blog Posts

Physicians Highlight How Big Pharma Games the System to Boost Profits and Block Competition from More Affordable Alternatives On Thursday, an op-ed in The Washington Post from William B. Feldman and Aaron S. Kesselheim, physicians at Brigham and Women’s Hospital and faculty members at Harvard Medical School, highlighted Big Pharma’s extensive patent abuse on brand […]

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS OVER $40 BILLION IN JUST ONE YEAR

05-23-2023 Blog Posts

New Analysis Highlights Urgency to Hold Big Pharma Accountable for Egregious Anti-Competitive Practices Last week, The American Economic Liberties Project and the Initiative for Medicines, Access & Knowledge (I-MAK) released a new analysis examining the staggering cost of Big Pharma’s patent abuse on the U.S. health care system and American patients. The analysis, titled “The […]

DOSE OF REALITY: BIG PHARMA TAX AVOIDANCE PRACTICES COME UNDER SCRUTINY IN SENATE FINANCE HEARING

05-12-2023 Blog Posts

Report Finds Big Pharma Games the System to Avoid Paying U.S. Taxes While Price-Gouging American Patients On Thursday, the U.S. Senate Finance Committee held a hearing titled, “Cross-border Rx: Pharmaceutical Manufacturers and U.S. International Tax Policy.” The hearing examined the pharmaceutical industry’s tax practices, in particular, following the passage of the Tax Cuts and Jobs Act of 2017. Ahead […]

THEY SAID IT! LAWMAKERS SLAM BIG PHARMA CEOS FOR EGREGIOUS PRICING OF BRAND NAME INSULINS

05-12-2023 Blog Posts

Brand Name Drug Giants Refuse to Rule Out Future Insulin Price Hikes On Wednesday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) held a hearing with executives from Big Pharma giants Novo Nordisk, Eli Lilly and Sanofi, who control 99 percent of the insulin marketplace. The hearing was titled, “The Need to Make Insulin […]

DOSE OF REALITY: SENATORS MUST HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS INSULIN PRICING PRACTICES

05-9-2023 Blog Posts

Lawmakers Have Opportunity to Grill Big Pharma Executives on Tactics Like “Shadow Pricing” that Drove Crisis of Insulin Affordability On Wednesday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) will get an opportunity to hold the Big Pharma companies that dominate the insulin market accountable for egregious pricing practices that pushed the […]

BIG PHARMA EARNINGS WATCH: PFIZER, MODERNA, ELI LILLY, NOVARTIS, GLAXOSMITHKLINE, ROCHE, AMGEN

05-9-2023 Blog Posts

Brand Name Drug Companies Continue to Hike Prices and Post Record Profits Rounding out the rest of Big Pharma’s earnings calls for the first quarter, brand name drug makers Pfizer, Moderna, Eli Lilly, Novartis, GlaxoSmithKline, Roche, and Amgen all reported revenue that topped Wall Street expectations, and several of the Big Pharma firms reported stronger […]

BIG PHARMA EARNINGS WATCH: MERCK, SANOFI, BRISTOL MYERS SQUIBB, ABBVIE AND ASTRAZENECA

05-3-2023 Blog Posts

More Big Pharma Giants Surpass Wall Street Expectations, Buoyed By Egregious Price Hikes on Blockbuster Products to Start the Year Another round of first-quarter earnings reports from Merck, Sanofi, Bristol Myers Squibb, AbbVie and AstraZeneca demonstrate that Big Pharma continues to surpass Wall Street’s expectations. All five Big Pharma giants topped Wall Street analysts’ earnings […]

BIG PHARMA WATCH: BIG PHARMA SPENT $8.1 BILLION ON ADS PUSHING HIGH-PRICED BRAND NAME PRESCRIPTION DRUGS IN 2022

05-1-2023 Blog Posts

Big Pharma Spending Binge Underscores Bipartisan Support for List Price Transparency in Direct-to-Consumer Advertising In case you missed it, on Monday, a new report in Fierce Pharma found Big Pharma spent nearly $8.1 billion on direct-to-consumer (DTC) advertising pushing brand name prescription drugs in 2022. Top spenders on high-priced brand name products include: Sanofi and Regeneron’s Dupixent: […]

DOSE OF REALITY: LIST PRICE TRANSPARENCY WILL HELP HOLD BIG PHARMA ACCOUNTABLE AND LOWER PRESCRIPTION DRUG PRICES FOR PATIENTS

04-25-2023 Blog Posts

Congress Should Advance Bipartisan, Market-Based Measures to Increase Transparency to Shine a Light on Brand Name Drug Companies’ Egregious Price Hikes and Launch Prices  Big Pharma companies are responsible for setting and increasing prices on the prescription drugs in their portfolio. Solutions that boost list price transparency can shine a light on the industry’s worst […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

04-24-2023 Blog Posts

Big Pharma Giant Kicks Off Q1 Earnings By Boasting “Strategic Price Increases Across All Franchises” Fueled Expectations Beat Last week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the first quarter of 2023. After brand name drug companies hiked prices on nearly 600 prescription drugs to start the year, Big Pharma […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.